Evaluative research and clinical trials
For over ten years, Epicentre has been conducting clinical trials on malaria treatment, both at the Mbarara, Uganda field research base, which has a reference laboratory, and at MSF intervention sites like those in the Democratic Republic of Congo and Liberia. The studies have looked at the safety and efficacy of artemisinin-based antimalarials in children and pregnant women (Uncomplicated malaria in DRC and Artemisinin African children). A clinical trial now underway in Mbarara will look at reducing the neurological sequelae of cerebral malaria in young childrena. (iNO trial)
With financial support from the ANRS and the Swiss section of MSF, Epicentre is finishing up a clinical trial comparing two antiretroviral regimens in TB-coinfected patients receiving anti-TB treatment that includes rifampicin in Mozambique (CARINEMO trial). Another safety trial is in preparation at the Mbarara, Uganda field research base, aimed at shortening the duration of anti-TB treatment through the use of higher rifampicin doses (RIFATOX trial), in collaboration with the University of London’s St. George’s Hospital.
Between 2003 and 2006, Epicentre conducted a multicenter phase II clinical trial on human African trypanosomiasis in the Democratic Republic of Congo and the Republic of the Congo, with support from the Dutch section of MSF, MSF International , and the DNDi. That trial compared the standard eflornithine treatment to nifurtimox-eflornithine combination therapy (NECT), and led to a change in treatment recommendations (Nifurtimox-Eflornithine Combination Therapy et recommandations OMS)